cystoscopy with clot evacuation. After adjusting for other factors, age and prior diagnosis of diabetes were not significantly associated with any complication. Patients treated in a rural setting were more likely to have all forms of complications compared to patients treated in a metropolitan area (p value <0.001).
INTRODUCTION AND OBJECTIVES: Narcotic abuse has continued to climb with studies showing those who abuse narcotics have obtained them through family members or friends. These direct connections are most likely to have received them directly from health care prescribers. A number of studies have looked at practice patterns within the field of urologic surgery. However, there are no studies that have quantified the effectiveness of analgesics in the immediate postoperative period.
METHODS: Patients undergoing ureteroscopy (URS) or transurethral resection of bladder tumor (TURBT) ambulatory cases were given discharge instructions to record details regarding their postoperative pain including: rating on a pain scale (1-10), day of pain, analgesic used, and post-medication pain scale. Patients were then called on post-operative day three and their results were discussed. Pre-and post-medication pain scores were evaluated and associated with mild (0-2 points of relief), moderate (3-4 points), or substantial (5 and greater points) improvements in pain. Statistical analysis was done using Fischer's exact and chi square testing.
RESULTS: Between July and September 2018, 70 patients were called in their immediate post-operative course. Of these patients, 36 who underwent either URS (22) or TURBT (14) were called and were willing to discuss their recorded findings. Of these patients, 21/36 (58%) admitted to any level of pain requiring medication. The majority of these patients were from URS as compared to TURBT (17 vs 4, p[0.006) . Of those given narcotics who had pain, 10/16 (62.5%) elected to initially take a narcotic no matter the pain score (Median 8 þ/-2.5, Range 3-10). When comparing pain score improvements (mild, moderate, substantial) between NSAIDs and narcotics (2 vs 15, 6 vs 4, 6 vs 5, p[0.015), a significant difference was found favoring NSAIDs for moderate to substantial relief. No patients reported taking narcotics after post-operative day 2.
CONCLUSIONS: This study describes the post-operative pain experienced after ambulatory upper and lower tract endoscopic procedures. While narcotics appear to be an effective analgesic for all types of pain, this study shows that it is no better if not less effective than NSAIDs for substantial pain relief. Given the current epidemic of opioid and prescription narcotic abuse, it is important to minimize narcotic prescriptions. This study shows that narcotics can be prescribed at a minimum level but also proves the benefits of other analgesics such as ketorolac for ambulatory endoscopic procedures of both upper and lower tracts. METHODS: The correlation between FGFR4 copy number (CN) and protein expression in ccRCC cell lines (A498, A704, and 769P) and clinical ccRCC specimens were estimated. CN was estimated using quantative real time polymerase chain reaction (qRT-PCR). Protein expressions in cell lines are evaluated using western blotting (WB) and ones in surgical specimens were done using immunohistochemistry (IHC). To investigate the roll of FGFR4 in ccRCC cells, WB, MTS assay and apoptotic assay were performed with or without FGFR4 inhibition by siRNA and pharmacological inhibitor BLU9931 treatment. To evaluate the potential for therapeutic target, BLU9931 administration for xenograft mouse model was performed.
RESULTS: IHCs showed FGFR4 expression in the cancer area was stronger than in the normal area (Fig 1.) . FGFR4 protein expression was positively correlated with genetic amplification in cell lines and surgical specimens (Fig 2. ). FGFR4 inhibition using siRNA or BLU9931 (1) suppressed phosphorylation of Akt and ERK1/2, (2) suppressed cell proliferation (Fig 4.) , and (3) induced apoptosis in vitro. BLU9931 administration for xenograft mouse model suppressed tumor growth and caused apoptosis under the tolerable dose (Fig 5.) .
CONCLUSIONS: FGFR4 is strongly expressed in ccRCC with FGFR4 genetic amplification. FGFR4 is a proliferative driver in ccRCC and the potential as a new therapeutic target.
